New malaria vaccine shows promise in first human trial in africa
⭐️ VACCINE ⭐️
Completed
This study tested a new malaria vaccine (PfSPZ-LARC2) in 75 healthy adults and children in Burkina Faso. The vaccine uses genetically weakened malaria parasites that grow in the liver but cannot cause blood-stage infection, aiming to trigger strong immunity safely. The main goal …
Phase: PHASE1 • Sponsor: Sanaria Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated May 03, 2026 10:04 UTC